

Stimulant Use Disorders

Mark Duncan MD

University of Washington







Speaker disclosures

✓ Any conflicts of interest?
✓None

The following series planners have no conflicts of interest:

- √ Jennifer Erickson DO
- √ Jess Fann MD
- ✓ Cherry Junn MD
- √ Chuck Bombardier PhD
- ✓ Cara Towle MSN RN MA
- ✓ David Minor
- ✓ Amanda Kersey PhD
- ✓ Lauren Miles




Objectives

- 1. Describe current trends of methamphetamine use in the state of Washington
- 2. Highlight the clinical impact of methamphetamine use
- 3. Increase knowledge on how to approach stimulant use disorder



Methamphetamine in WA: 个 Deaths

Drug-caused death rates per 100,000 state residents








Methamphetamine in WA: often mixed with other drugs

Death rates per 100,000 state residents, methamphetamine deaths detail



- Methamphetamine & Alcohol or Benzos or Barbiturates (no C or O)
- Methamphetamine & Cocaine
- Methamphetamine (no C or O or ABB)
- Opioids & Cocaine & Methamphetamine
- Opioids & Methamphetamine

Meth

- 6.46 deaths per 100,000
- 23% of all drug poisoning

*Opioids 10.79 (37% of all drug poisoning)

Opioids and Meth

- 8.18 deaths per 100,000
- 27% of all drug poisoning

*Opioids 10.79 (37% of all drug poisoning)



Helpful Things to Know about Meth

- How is it used: smoking, swallowing, snorting, injecting
- Binge pattern
 - Functional
 - Pleasurable
- Detectable in urine drug tests:1-4 days

Short-Term Effects	Long-Term Effects			
Increased wakefulness Decreased appetite Increased breathing rate Increased heart rate Increase blood pressure Increase body temperature	Extreme weight loss Addiction Severe dental problems Intense itching, leading to skin sores from scratching Anxiety Changes in brain structure and function Confusion Memory loss Sleeping problems Violent behavior Paranoia—extreme and unreasonable distrust of others Hallucinations—sensations and images that seem real though they aren't			

NIDA. 2019, May 16. Methamphetamine DrugFacts. Retrieved from https://nida.nih.gov/publications/drugfacts/methamphetamine on 2022, October 7

Peavy KM, Banta-Green C, Owens M. Opioids and Stimulants: What Are They and How Are People Using Them? Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, April 2021.



Impact of TBI and Chronic Meth Use on Brain are similar

- Structural: both are linked with reduction in hippocampal vol and damage to prefrontal cortex, limbic, and paralimbic cortices
- ▶ Biochemical: imbalance in excitatory and inhibitory homeostasis
- Cellular: inflammation and apoptosis

When combined → increase in neuronal damage?



27yo M with a history of bacterial meningitis in college presenting for a STI check/treatment after having sex with multiple sexual partners during a binge on methamphetamine. He is using a 2 days a week he admits he should stop using.


What would you do?

- A. Refer to a residential addiction treatment facility
- B. Refer to an outpatient addiction treatment facility
- c. Start a medication to treat his methamphetamine use disorder
- D. Monitor use → not a use disorder
- E. Other




Interest in Reducing Use? (Meth is Very Reinforcing)

Interest in reducing or stopping opioid use among main drug heroin n=514



Interest in reducing or stopping *stimulant* use among main drug meth, n=281





Everyone has their own clock for change


- ► Temper Provider Expectations
- Remembering the good news: opioid/stimulants users enrolled in opioid treatment are enrolled in treatment.
 - ▶ Keep them there. Avoid discharge for stimulant use.
- Continue exploring reasons to change.
- Leverage long lasting and important counseling relationships to explore change.



Meth - Services Requested

What types of help would you want if they were easy to get?"

n=136 among main drug meth, past week meth use, & somewhat/very interested in reducing stimulant use





Meth - Services Requested

What types of help would you want if they were easy to get?"

n=136 among main drug meth, past week meth use, & somewhat/very interested in reducing stimulant use

Takeaway: Offer a range of services


Counseling
Care Navigation
Mental Health Treatment
Medications
Medical Treatment?





Safer-use Strategies: Uppers/Stimulants

Stimulants are "uppers" and include cocaine, crack, meth, MDMA (Molly) and bath salts, as well as prescribed drugs like Ritalin and Adderall. Here are some tips to help you stay safer and healthier no matter how you choose to change your use. Using more safely does not mean that you remove all risks, including death, but it can help you reduce your drug-related harm. You are worth it!





Treatment Options

- ► 1st Line-Psychosocial Support
 - More consistent effect on
 - ► Reducing stimulant use
 - Longer periods of abstinence
 - ► Effects may last longer or can be more durable
- ► 2nd Line-Pharmacotherapy
 - Less consistent effects on
 - ► Reducing use or supporting abstinence



Treatment Options

- ► 1st Line-Psychosocial Support
 - Contingency Management
 - Significant results: OUD + Cocaine → CM resulted in a 41% increase in abstinence
 - ► Effects do not stick around



- ► CBT
- ▶ 12 Step Groups



Contingency Management

- ► Targets <u>specific behaviors</u>
 - Attendance
 - ► Taking medication
 - Substance use
- Provides the person with an incentive for doing the target behavior.
- ► Allows for a celebration when target behavior is complete.
- App-based delivery?





24yo F with a history of possible ADHD in an intensive outpatient treatment program. Methamphetamine use continues to be used mostly around her work earning money delivering food all night.

What medication might you offer?

- A. Bupropion
- B. Mirtazapine
- c. Methylphenidate
- D. Lisdexamfetamine
- E. None



Treatment Options

- Medications for stimulant use disorder
 - ► No FDA approved medication
 - Many have been tried, participant dropouts common
 - ► Antidepressants
 - Antipsychotics
 - **►** Stimulants
 - ► Anticonvulsants
 - ► Other SUD meds



Summary of Meds for Methamphetamine Use Disorder

	Abstinence	Use	Retention	Harms
All Antidepressants	**	Ø	**	*
Aminoketone: Bupropion	*	*	**	Ø
Atypical Antidepressant: Mirtazapine	NA	Ø	Ø	Ø
SSRI: Sertraline	Ø	NA	Ø	NA
Atypical Antipsychotics: Aripiprazole	Ø	*	Ø	Ø
Psychostimulants and Other Medications for ADHD				
All Psychostimulants:	*	Ø	*	NA
Modafinil, Dexamphetamine, Methylphenidate				
Methylphenidate	NA	*	*	NA
Atomoxetine	NA	Ø	Ø	Ø
All Anticonvulsant and Muscle Relaxants: Baclofen, Gabapentin, Topiramate	ø	ø	ø	Ø
Topiramate	NA	*	*	*
Medications used for other substance use disorders				
Naltrexone	Ø	*	*	**
Varenicline	NA	Ø	ø	Ø

Shading represents the direction of effect:

(No color) U Grey M Green E Red

Unclear No difference Evidence of benefit Favors placebo Symbols represent the strength of the evidence:

NA No evidence or not applicable

Ø Insufficient

t Low

★★ Moderate

★★★ High



Treatment Options

- Bupropion (Wellbutrin, Zyban)-2008
 - ▶ 12 weeks, 3 days in clinic (urine drug screens/assessments/90 min CBT group therapy)
 - ▶ Bupropion SR 150-300mg qday
 - Results: In MALE participants using 18 days/30days in the Bupropion arm about 70% had a week free of meth vs 40% in the placebo
- Mirtazapine (Remeron)-2019
 - ▶ 24 weeks treatment and 12 weeks follow-up, interest in reducing or stopping meth use
 - Seen weekly for meth urine testing, 30min CBT/MI session
 - Cisgender men and transgender women who have sex with men
 - Mirtazapine 30mg qhs, delivered via wise pill dispenser
 - ► Results: reduced high risk sex, reduced urine drug tests (RR 0.75)



Treatment Options

- Methylphenidate
 - Sample of 4 RCTs: Methylphenidate vs Placebo, max dose 54mg qday
 - Reduced amphetamine positive urine samples in 2 or 4 studies
 - Reduced cravings
 - One study showed more positive effect in more severe use at baseline
- Topiramate
 - ▶ 2 RCTs, N=202, one study had a brief "compliance enhancement tx"
 - ► Topiramate 200mg qday vs Placebo 10-12 weeks.
 - ► Results from 2012-Elkashef-reduced weekly meth levels by > 25% (urine concentrations) and severity of dependence
 - Results from 2016 Rezaei-less positive urines, reduced addiction severity and cravings



ADHD Pharmacotherapy

Methylphenidate

- ► High doses (up to 180mg qday ER, FDA max 72):
- ▶ Participants: incarcerated population, men, amphetamine addicted
- Results
 - ► Reduced methamphetamine use
 - ► High drop out rate



Vivitrol + Bupropion

- Population: Mod to Severe Meth Use Disorder
- Excluded
 - ► In current SUD tx
 - Expected need for opioid tx
- Intervention
 - ▶ 12 weeks
 - Vivitrol + Bupropion XL 450mg qday
 - Clinic visits 2x's/week
 - Urine samples
 - Assessments
 - ▶ Weekly clinician visits to monitor side effects, encourage abstinence
 - Smart phone app monitored Bupropion adherence



Vivitrol + Bupropion

- Results
 - ▶ 16.5% of participants achieved negative drug screens by week 5 and 6
 - ▶ 11.4% achieved meth negative urine drug screens by week 11 and 12.
 - NNT-9
 - ► (NNT for Naltrexone to prevent return to any drinking for AUD is 20)




Best Predictors of Success

- Infrequent use at start and/or early abstinence within 2 weeks
- Medication adherence
 - ► More likely to open pill bottles on visit days
 - ► Increased age
- Psychosocial participation



Treatment Approach





Treatment Options: Stimulants

- ► Goal: to keep the patient engaged and monitor use.
 - Meet patient where they are at.
 - Abstinence
 - Detox-typically not needed
 - ► Mutual Help Groups-CA
 - Inpatient or specialty treatment referral
 - Contingency Management is most helpful



Books to Learn More about Methamphetamine Use Disorder

- The Least of Us: True Tales of America and Hope in the Times of Fentanyl and Meth
 - by Sam Quinones
- Beautiful Boy: A Father's Journey Through His Son's Addiction
 - by David Sheff
- ► Tweak: Growing Up on Methamphetamine
 - by Nic Sheff

